Trade Names:Alphagan P- Solution 0.15%Apo-Brimonidine (Canada)PMS-Brimonidine Tartrate (Canada)ratio-Brimonidine (Canada)
Reduces aqueous humor production and increases uveoscleral outflow.
Lowers IOP in open-angle glaucoma or ocular hypertension.
Coadministration of MAOIs.
Ophthalmic Instill 1 drop into affected eye(s) 3 times daily (approximately 8 h apart). If using other topical ophthalmic drugs, separate each medication by at least 5 min.
Store at controlled room temperature (59° to 77°F). Keep container tightly closed.
Brimonidine may reduce pulse and BP; use with caution.CNS depressants (eg, alcohol, anesthetics, barbiturates, opiates, sedative)
Additive or potentiating CNS depressant effect.MAOIs
Concurrent use contraindicated; discontinue MAOIs at least 14 days before initiating therapy.Tricyclic antidepressants
May decrease the effect of brimonidine by altering the metabolism and uptake of circulating amines.
None well documented.
Headache; fatigue; drowsiness; dizziness; depression; anxiety; syncope.
Dry mouth; ocular hyperemia, burning, and stinging; blurred vision; foreign body sensation; conjunctival follicles; ocular allergy; ocular pruritus; corneal staining and erosion; photophobia; eyelid erythema and edema; ocular aching and pain; ocular dryness; tearing; conjunctival edema; blepharitis; ocular irritation; conjunctival blanching; abnormal vision; lid crusting; conjunctival hemorrhage; abnormal taste; conjunctival discharge; nasal dryness.
Upper respiratory tract symptoms.
Asthenia; muscle pain.
Ensure that IOPs have been measured and documented in the patient's record.
Category B .
Safety and efficacy not established in children younger than 2 yr of age.
Use with caution.
Use with caution.
Wait at least 15 min after instilling brimonidine before inserting contact lenses.
Copyright © 2009 Wolters Kluwer Health.